Proteomics serves a crucial and accelerating function throughout the entire Drug Discovery pipeline, starting with the identification and validation of novel therapeutic targets. Since proteins are the primary functional molecules and the most common drug targets, comparative proteomic analysis between diseased and healthy cells can quickly highlight proteins that are overexpressed, malfunctioning, or aberrantly modified, making them ideal candidates for intervention.

Furthermore, proteomics is indispensable for characterizing a drug's mechanism of action (MoA). By analyzing global protein changes in cells following drug exposure, researchers can confirm whether the compound interacts with its intended target (on-target effects) and detect unintended interactions (off-target effects) that could lead to toxicity. This early and comprehensive assessment of efficacy and safety, often through advanced techniques like chemoproteomics, allows pharmaceutical teams to accelerate the lead optimization process and reduce the high attrition rates associated with preclinical development.

Related Reports